Overview: A New Immunotherapy Candidate in Follicular Lymphoma The FDA has awarded Fast Track designation to EO2463, Enterome’s novel immunotherapy designed for follicular lymphoma (FL), an indolent but often relapsing form of non-Hodgkin lymphoma. Grounded in promising interim data from the SIDNEY phase 2 trial, EO2463 represents a strategic effort to harness the immune system…